Leerink Partners Remains Sidelined on OvaScience (OVAS) Following 1Q
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- Wall St futures muted as oil gains curb risk appetite after S&P record close
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
OvaScience Reports First Quarter 2016 Financial Results
May 5, 2016 4:00 PM EDTAUGMENT treatment gains traction in growing fertility market and Company expands access internationally
New research supports AUGMENT and pipeline treatments
WALTHAM, Mass.--(BUSINESS WIRE)-- OvaScienceSM (NASDAQ: OVAS), a global fertility company focused on the discovery, development and commercialization of new treatment options, today reported its first quarter 2016 financial results and highlighted recent accomplishments.
OvaScience is currently focused on building our operational platform to support the expansion of the AUGMENT treatment. We are focusing our AUGMENT commercial efforts to target Canada and Japan as our... More
